BRAF and neoplasm: Importantly, the MITF‐low/proliferative subtype, characterised by an absence of the expression of immune‐response genes, had only BRAF/NRAS‐mutated samples and more tumours with CDKN2A deletions, and was significantly associated with a poorer prognosis.